The 2nd ILEP Symposium on the Optimal Lipid Lowering Management of patients at very high CVD risk
Lodz, Poland (22nd April 2024)

11.30 – 12.00

Welcome coffee and tea

12.00 – 13.15

SESSION 1: Intensive statin therapy vs intensive lipid lowering combination therapy - why does this switch is necessary?

Chairs: Prof. Jacek Jóźwiak (Poland), Prof. Ivan Pećin (Croatia)

12.00 – 12.15

Lipid disorders in Europe – where we are in 2024 and why we are so ineffective?
(Prof. Daniel Pella, Slovak Republic)

12.15 – 12.30

Effective diagnosis of lipid disorders. LDL-C, non-HDL or ApoB? What new PSDL/PoLA 2024 recommendations say on this?
(Prof. Anca Stoian, Romania)

12.30 – 12.45

Intensive statin therapy vs combination lipid lowering therapy? 20 years of experience, 20 years of failure? (Prof. Michal Vrablik, Czechia).

12.45 – 13.00

Optimal, upfront lipid lowering combination therapy in ACS patients peri-procedurally and early during the hospitalization - how, when and what data do we have? (Prof. Dariusz Dudek, Poland).

13.00 – 13.15


13.15 – 14.30

SESSION 2: Recent results and the place of new drugs in lipid lowering therapy - bempedoic acid, PCSK9 inhibitors, inclisiran, perspective drugs.

Chairs: Prof. Michal Vrablik (Czechia), Prof. Robert Gil (Poland)

13.15 – 13.30

Most recent data on PCSK9 inhibitors in the lipid disorders management. The way to be finally effective for selected (unfortunately) patients?
(Prof. Dov Gavish, Israel)

13.30 – 13.45

The place of PCSK9 modulators (PCSK9Is and inclisiran) in the lipid lowering therapy. Another way to be on LDL-C target?
(Prof. Charalambos Vlachopoulos, Greece).

13.45 – 14.00

The place and role of the bempedoic acid in the lipid lowering management. Statin intolerant, high risk patients, or both?
(Prof. Maciej Banach, Poland)

14.00 – 14.15

Obicetrapib, oral PCSK9, CRISPR, vaccines, and their possible perspective role in LLT
(Prof. Gustavs Latkovskis, Latvia)

14.15 – 14.30


14.30 – 15.15

Light Lunch and Networking

15.15 – 16.30

SESSION 3: How to increase the number of patients treated with innovative therapies and overcome the reimbursement criteria. Can we learn from each other?

Chairs: Prof. Gustavs Latkovskis, (Latvia), Prof. Charalambos Vlachopoulos (Greece)

15.15 - 15.30

The current situation on the reimbursement criteria of PCSK9 modulators in CEE and other European countries. Can we learn from each other to be more effective?
(Prof. Piotr Jankowski, Poland)

15.30 – 15.45

Lipid lowering therapy and atheroma plaque. Angio-CT, CAC score, soft atheroma plaque – whether they may help to extend indications for innovative therapies?
(Prof. Robert Gil, Poland)

15.45 – 16.00

New guidelines on Lp(a). The role in CVD risk assessment and way to reduce it. Whether Lp(a) should be also included in PCSK9ms reimbursement programs?
(Prof. Ivan Pećin, Croatia)

16.00 – 16.15

Very high-risk primary prevention patients, high risk ASCVD patients without an event – why cannot they benefit from the innovative therapies? Do we have data to support these indications?
(Prof. Krzysztof Dyrbuś, Poland)

16.15 – 16.30


16.30 – 17.45

SESSION 4: Whether and how can we overcome the well-recognized obstacles of ineffective management, like nonadherence, therapeutical inertia, statin intolerance, lack of drugs availability, lack of knowledge.

Chairs: Prof. Daniel Pella (Slovakia), Prof. Agata Bielecka-Dąbrowa (Poland)

16.30 – 16.45

Non-adherence as an independent CVD risk factor. How to optimally measure therapy adherence and the ways to improve this.
(Prof. Marek Gierlotka, Poland)

16.45 – 17.00

Management of statin intolerance in 2024. Can we be effective with LDL-C goal achievement in most of the patients?
(Prof. Peter Penson, UK)

17.00 – 17.15

Lipid lowering therapy in challengeable groups of patients – T2DM and elderly. Whether (upfront) lipid lowering combination therapy might be a solution?
(Prof. Dan Gaita, Romania)

17.15 – 17.30

Patients with metabolic disorders and/or statin intolerance. Pitavastatin – the way to personalize lipid lowering therapy ?
(Prof. Niki Katsiki, Greece)

17.30 – 17.45


17.45 – 17.55

Short coffee break

17.55 – 18.55

SESSION 5: Presentation of the 2024 ILEP Position Paper on the Optimal use of lipid-lowering therapy in very high and extremely high-risk patients.

Chairs: Prof. Niki Katsiki (Greece), Prof. Anca Stoian (Romania)

17.55 – 18.20

2024 ILEP Position Paper on the Optimal use of lipid-lowering therapy in very high and extremely high-risk patients. (Prof. Maciej Banach, Poland)

18.20 – 18.45

Round-table debate and discussion (all the experts)

18.45 - 19.00

Take-home Conclusions